Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant (Gardasil) (1 trial)
blinatumomab (blincyto) (1 trial)
ponatinib (iclusig) (1 trial)
cd19 car-t cells (1 trial)
Leukemia (Phase 2)
Leukemia, Lymphoid (Phase 2)
Papilloma (Phase 3)
Papillomavirus Infections (Phase 3)
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)
Respiratory Tract Infections (Phase 3)
Trials (4 total)
Trial APIs (4 total)